BD announced the results of a new survey revealing that 74% of women in Canada have delayed a gynecology visit, with 83% wanting more accessible and less invasive cervical cancer testing options, including at-home self-collection for human papillomavirus (HPV) tests.
BD announced today Health Canada approval of the BD Onclarity™ HPV Assay for human papillomavirus (HPV) testing for the use of self-collected vaginal specimens at home.
Mackenzie Health recently launched BD Alaris™ EMR Bidirectional Interoperability, which allows for two-way information flow between an IV pump and a patient’s electronic medical record.
Humber and BD are working together to reshape the landscape of health care workforce development and address the evolving needs of the industry along with health human resources.
BD-Canada is aware of the U.S. FDA issuing Safety Communication stating concern that certain plastic syringes may not provide consistent and adequate quality or performance.
The kidney care community advocates for more cost-effective treatment options, which offer a better quality of life and improved outcomes, although several obstacles hinder significant progress in improving kidney failure treatment.
Cervical cancer is one of the few cancers that is almost completely preventable through systematic screening programs, early detection with HPV testing and vaccination. Our generation holds the incredible potential to seize the opportunity to eradicate cervical cancer within our lifetime.
London Health Sciences Centre (LHSC) and St. Joseph’s Heath Care London (St. Joseph’s) are celebrating the installation of a Total Laboratory Automation (TLA) system within the clinical microbiology laboratory.
The program led by 19 to Zero aims to support point-of-care testing needs beyond COVID-19 for urban and rural communities in Alberta through education and diagnosis at clinics.
BD announced that it had received Authorization under the Interim Order from Health Canada for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A and B and Respiratory Syncytial Virus (RSV) to help combat a potential “tripledemic” in the upcoming respiratory virus season.
The Groshong® PICC, Proven performance coupled with proven effectiveness. For years Groshong® PICCs have set the standard in closed-system, vascular access delivery.
This webinar will focus on lessons learned and best practices of implementing an IV workflow management system highlighting UNC Health’s latest AJHP publication outcomes on the power of remote verification of compounded medications.
This webinar will focus on lessons learned and best practices of implementing an IV workflow management system highlighting UNC Health’s latest AJHP publication outcomes on the power of remote verification of compounded medications.
This webinar will review sterile compounding regulations per USP, ASHP Guidelines, ISMP Guidelines, and The Joint Commission, describe how IV Workflow Management Systems can support USP Compliance through documentation, label requirements, and workflow.
This webinar will review sterile compounding regulations per USP, ASHP Guidelines, ISMP Guidelines, and The Joint Commission, describe how IV Workflow Management Systems can support USP Compliance through documentation, label requirements, and workflow.
The activated hyperlink may be to a third-party website. Clicking on the link may allow third parties to collect or share data about you. We do not control these third-party websites and are not responsible for their privacy statements. When you leave this website, we encourage you to read the privacy notice of every website you visit.
Where the website is managed by another BD company, please note that it may be governed by different laws and policies, and may feature products and services that are not available locally. Please contact your local BD representative if you have any questions or should you require further support.
Toll-free: 866.979.9408 
canada@bd.com 
BD - Canada 2100 Derry Road West Suite 100 Mississauga, ON L5N 0B3 
